A 3-marker index improves the identification of iron disorders in CKD anaemia

PLoS One. 2014 Feb 19;9(2):e84144. doi: 10.1371/journal.pone.0084144. eCollection 2014.

Abstract

Background: Iron disorders are common and complex in chronic kidney disease (CKD). We sought to determine whether a 3-marker index would improve the classification of iron disorders in CKD anaemia.

Methods: We studied the association between Hb level and iron indexes combining 2 or 3 of the following markers: serum ferritin (<40 ng/mL), transferrin saturation (TSAT<20%) and total iron binding capacity (TIBC<50 µmol/L) in 1011 outpatients with non-dialysis CKD participating in the Nephrotest study. All had glomerular filtration rates measured (mGFR) by (51)Cr-EDTA renal clearance; 199 also had hepcidin measures.

Results: The TSAT-TIBC-ferritin index explained Hb variation better than indexes combining TSAT-TIBC or ferritin-TSAT. It showed hypotransferrinaemia and non-inflammatory functional iron deficiency (ID) to be more common than either absolute or inflammatory ID: 20%, 19%, 6%, and 2%, respectively. Hb was lower in all abnormal, compared with normal, iron profiles, and decreased more when mGFR was below 30 mL/min/1.73 m(2) (interaction p<0.0001). In patients with mGFR<30 mL/min/1.73 m(2), the Hb decreases associated with hypotransferrinaemia, non-inflammatory functional ID, and absolute ID were 0.83±0.16 g/dL, 0.51±0.18 and 0.89±0.29, respectively. Compared with normal iron profiles, hepcidin was severely depressed in absolute ID but higher in hypotransferrinaemia.

Conclusions: The combined TSAT-TIBC-ferritin index identifies hypotransferrinaemia and non-inflammatory functional ID as the major mechanisms of iron disorders in CKD anaemia. Both disorders were associated with a greater decrease in Hb when mGFR was <30 mL/min/1.73 m(2). Taking these iron profiles into account may be useful in stratifying patients in clinical trials of CKD anaemia and might improve the management of iron therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anemia / blood
  • Anemia / complications*
  • Anemia / metabolism*
  • Anemia / physiopathology
  • Biomarkers / blood
  • Biomarkers / metabolism
  • Female
  • Ferritins / blood
  • Glomerular Filtration Rate
  • Hemoglobins / metabolism
  • Humans
  • Iron / metabolism*
  • Kidney / physiopathology
  • Male
  • Middle Aged
  • Renal Insufficiency, Chronic / complications*
  • Risk Factors
  • Sex Factors
  • Transferrin / metabolism

Substances

  • Biomarkers
  • Hemoglobins
  • Transferrin
  • Ferritins
  • Iron

Grants and funding

The NephroTest CKD cohort study is supported by the following grants: INSERM GISIReSP AO 8113LS TGIR (BS), French Ministry of Health AOM 09114 (MF), INSERM AO 8022LS (BS), Agence de la Biomédecine R0 8156LL (BS), AURA (MF), and Roche 2009-152-447G (MF). The NephroTest initiative was also sponsored by unrestricted grants from F. Hoffman-La Roche Ltd (LM). BS benefits from an Investigator Sponsored Study from Amgen (20119011). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.